Enhancement of Classic Kaposi’s Sarcoma Growth after Intralesional Injections of Desferrioxamine

We have previously shown that iron may be involved in the pathogenesis of Kaposi’s sarcoma (KS) and that the iron chelator desferrioxamine (DFO) inhibits the growth and induces the apoptosis of KS cells in vitro. We treated an 85-year-old man with classic KS with 5 weekly intralesional injections of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Dermatology (Basel) 2002-01, Vol.204 (4), p.290-292
Hauptverfasser:	Simonart, T., Boelaert, J.R., van Vooren, J.P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic agents Apoptosis - drug effects Biological and medical sciences Case Report Chemotherapy Deferoxamine - pharmacology Deferoxamine - therapeutic use Dermatology Humans Injections, Intralesional Iron Chelating Agents - pharmacology Iron Chelating Agents - therapeutic use Male Medical sciences Pharmacology. Drug treatments Sarcoma, Kaposi - drug therapy Skin Neoplasms - drug therapy Tumors of the skin and soft tissue. Premalignant lesions
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!